{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T20:04:32Z","timestamp":1769803472148,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Forensic Toxicol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11419-025-00745-0","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:05:30Z","timestamp":1765807530000},"page":"130-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative determination of suvorexant, lemborexant, and daridorexant in human plasma using a MonoTip C18 and gas chromatography-mass spectrometry"],"prefix":"10.1007","volume":"44","author":[{"given":"Koichi","family":"Aoyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3181-9035","authenticated-orcid":false,"given":"Chika","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiko","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kumazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Nakauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motofumi","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"745_CR1","first-page":"264","volume":"39","author":"T Bennett","year":"2014","unstructured":"Bennett T, Bray D, Neville MW (2014) Suvorexant, a dual orexin receptor antagonist for the management of insomnia. P T 39:264\u2013266","journal-title":"P T"},{"key":"745_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/10600280211008492","volume":"56","author":"K Waters","year":"2022","unstructured":"Waters K (2022) Review of the efficacy and safety of lemborexant, a dual receptor orexin antagonist (DORA), in the treatment of adults with insomnia disorder. Ann Pharmacother 56:213\u2013221. https:\/\/doi.org\/10.1177\/10600280211008492","journal-title":"Ann Pharmacother"},{"key":"745_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27186041","volume":"27","author":"W Ziemich\u00f3d","year":"2022","unstructured":"Ziemich\u00f3d W, Grabowska K, Kurowska A, Bia\u0142a G (2022) A comprehensive review of Daridorexant, a dual-orexin receptor antagonist as new approach for the treatment of insomnia. Molecules 27:6041. https:\/\/doi.org\/10.3390\/molecules27186041","journal-title":"Molecules"},{"key":"745_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13902","volume":"32","author":"C Muehlan","year":"2023","unstructured":"Muehlan C, Roch C, Vaillant C, Dingemanse J (2023) The orexin story and orexin receptor antagonists for the treatment of insomnia. J Sleep Res 32:e13902. https:\/\/doi.org\/10.1111\/jsr.13902","journal-title":"J Sleep Res"},{"key":"745_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.14035","volume":"32","author":"D Riemann","year":"2023","unstructured":"Riemann D, Espie CA, Altena E, Arnardottir ES, Baglioni C, Bassetti CLA, Bastien C, Berzina N, Bjorvatn B, Dikeos D, Dolenc Groselj L, Ellis JG, Garcia-borreguero D, Geoffroy PA, Gjerstad M, Gon\u00e7alves M, Hertenstein E, Hoedlmoser K, Hion T, Holzinger B, Janku K, Jansson-fr\u00f6jmark M, J\u00e4rnefelt H, Jernel\u00f6v S, Jennum PJ, Khachatryan S, Krone L, Kyle SD, Lancee J, Leger D, Lupusor A, Marques DR, Nissen C, Palagini L, Paunio T, Perogamvros L, Pevernagie D, Schabus M, Shochat T, Szentkiralyi A, Van Someren E, Van Straten A, Wichniak A, Verbraecken J, Spiegelhalder K (2023) The European insomnia guideline: an update on the diagnosis and treatment of insomnia 2023. J Sleep Res 32:e14035. https:\/\/doi.org\/10.1111\/jsr.14035","journal-title":"J Sleep Res"},{"key":"745_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1620\/tjem.212.239","volume":"212","author":"K Nomura","year":"2007","unstructured":"Nomura K, Nakao M, Sato M, Yano E (2007) The long-term prescription of benzodiazepines, psychotropic agents, to the elderly at a University Hospital in Japan. Tohoku J Exp Med 212:239\u2013246. https:\/\/doi.org\/10.1620\/tjem.212.239","journal-title":"Tohoku J Exp Med"},{"key":"745_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.psychres.2016.01.040","volume":"237","author":"N Takeshima","year":"2016","unstructured":"Takeshima N, Ogawa Y, Hayasaka Y, Furukawa TA (2016) Continuation and discontinuation of benzodiazepine prescriptions: a cohort study based on a large claims database in Japan. Psychiatry Res 237:201\u2013207. https:\/\/doi.org\/10.1016\/j.psychres.2016.01.040","journal-title":"Psychiatry Res"},{"key":"745_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029641","volume":"9","author":"A Takano","year":"2019","unstructured":"Takano A, Ono S, Yamana H, Matsui H, Matsumoto T, Yasunaga H, Kawakami N (2019) Factors associated with long-term prescription of benzodiazepine: a retrospective cohort study using a health insurance database in Japan. BMJ Open 9:e029641. https:\/\/doi.org\/10.1136\/bmjopen-2019-029641","journal-title":"BMJ Open"},{"key":"745_CR9","unstructured":"Ministry of Health, Labour and Welfare, Tokyo, Japan. Revision of Medical Fees in 2018 (medical treatment and pharmaceutical). https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-12404000-Hokenkyoku-Iryouka\/0000193708.pdf. Accessed May 2025."},{"key":"745_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/pcn.13525","volume":"77","author":"M Takeshima","year":"2023","unstructured":"Takeshima M, Yoshizawa K, Enomoto M, Ogasawara M, Kudo M, Itoh Y, Ayabe N, Takaesu Y, Mishima K (2023) Effects of Japanese policies and novel hypnotics on long-term prescriptions of hypnotics. Psychiatry Clin Neurosci 77:264\u2013272. https:\/\/doi.org\/10.1111\/pcn.13525","journal-title":"Psychiatry Clin Neurosci"},{"key":"745_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161996","volume":"11","author":"K Ichikura","year":"2016","unstructured":"Ichikura K, Okumura Y, Takeuchi T (2016) Associations of adverse clinical course and ingested substances among patients with deliberate drug poisoning: a cohort study from an intensive care unit in Japan. PLoS ONE 11:e0161996. https:\/\/doi.org\/10.1371\/journal.pone.0161996","journal-title":"PLoS ONE"},{"key":"745_CR12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14329","volume":"13","author":"H Ito","year":"2021","unstructured":"Ito H, Ogawa Y, Shimojo N, Kawano S (2021) Suvorexant poisoning in a patient with cirrhosis and renal failure. Cureus 13:e14329. https:\/\/doi.org\/10.7759\/cureus.14329","journal-title":"Cureus"},{"key":"745_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.legalmed.2024.102527","volume":"71","author":"G Yamasaki","year":"2024","unstructured":"Yamasaki G, Ueno Y, Takahashi M, Kondo T (2024) Fatal acute lemborexant poisoning: an autopsy case report. Leg Med (Tokyo) 71:102527. https:\/\/doi.org\/10.1016\/j.legalmed.2024.102527","journal-title":"Leg Med (Tokyo)"},{"key":"745_CR14","doi-asserted-by":"publisher","DOI":"10.4103\/jad.jad_4_25","volume":"14","author":"D Katto","year":"2025","unstructured":"Katto D, Ito H, Kobayashi D (2025) Lemborexant overdose: a case report. J Acute Dis 14:3. https:\/\/doi.org\/10.4103\/jad.jad_4_25","journal-title":"J Acute Dis"},{"key":"745_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jchromb.2015.07.056","volume":"1002","author":"SA Breidinger","year":"2015","unstructured":"Breidinger SA, Simpson RC, Mangin E, Woolf EJ (2015) Determination of suvorexant in human plasma using 96-well liquid\u2013liquid extraction and HPLC with tandem mass spectrometric detection. J Chromatogr B 1002:254\u2013259. https:\/\/doi.org\/10.1016\/j.jchromb.2015.07.056","journal-title":"J Chromatogr B"},{"key":"745_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jchromb.2016.10.042","volume":"1040","author":"M Carson","year":"2017","unstructured":"Carson M, Kerrigan S (2017) Quantification of suvorexant in urine using gas chromatography\/mass spectrometry. J Chromatogr B 1040:289\u2013294. https:\/\/doi.org\/10.1016\/j.jchromb.2016.10.042","journal-title":"J Chromatogr B"},{"key":"745_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/jat\/bkw111","volume":"41","author":"M Iqbal","year":"2017","unstructured":"Iqbal M, Ezzeldin E, Khalil NY, Al-Rashood STA, Al-Rashood KA (2017) Simple and highly sensitive UPLC-ESI-MS\/MS assay for rapid determination of suvorexant in plasma. J Anal Toxicol 41:114\u2013120. https:\/\/doi.org\/10.1093\/jat\/bkw111","journal-title":"J Anal Toxicol"},{"key":"745_CR18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/jat\/bkw132","volume":"41","author":"S Sullinger","year":"2017","unstructured":"Sullinger S, Bryand K, Kerrigan S (2017) Identification of suvorexant in urine using liquid chromatography-quadrupole\/time-of-flight mass spectrometry (LC-Q\/TOF-MS). J Anal Toxicol 41:224\u2013229. https:\/\/doi.org\/10.1093\/jat\/bkw132","journal-title":"J Anal Toxicol"},{"key":"745_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/jat\/bkx110","volume":"42","author":"B Waters","year":"2018","unstructured":"Waters B, Hara K, Ikematsu N, Takayama M, Matsusue A, Kashiwagi M, Kubo S (2018) Tissue distribution of suvorexant in three forensic autopsy cases. J Anal Toxicol 42:276\u2013283. https:\/\/doi.org\/10.1093\/jat\/bkx110","journal-title":"J Anal Toxicol"},{"key":"745_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jchromb.2018.05.006","volume":"1091","author":"B Skillman","year":"2018","unstructured":"Skillman B, Kerrigan S (2018) Quantification of suvorexant in blood using liquid chromatography-quadrupole\/time of flight (LC-Q\/TOF) mass spectrometry. J Chromatogr B 1091:87\u201395. https:\/\/doi.org\/10.1016\/j.jchromb.2018.05.006","journal-title":"J Chromatogr B"},{"key":"745_CR21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/cpt.1046","volume":"104","author":"C Muehlan","year":"2018","unstructured":"Muehlan C, Heuberger J, Juif P, Croft M, van Gerven J, Dingemanse J (2018) Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study. Clin Pharmacol Ther 104:1022\u20131029. https:\/\/doi.org\/10.1002\/cpt.1046","journal-title":"Clin Pharmacol Ther"},{"key":"745_CR22","first-page":"194","volume":"6","author":"S Sriram","year":"2019","unstructured":"Sriram S, Vijaya RJ, Santosh KT (2019) Development and validation of high performance liquid chromatographic method for the determination of suvorexant in rabbit plasma by HPLC-UV detection. J Emerg Technol Innov Res 6:194\u2013203","journal-title":"J Emerg Technol Innov Res"},{"key":"745_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jat\/bkz083","volume":"44","author":"B Skillman","year":"2020","unstructured":"Skillman B, Kerrigan S (2020) Identification of suvorexant in blood using LC-MS-MS: important considerations for matrix effects and quantitative interferences in targeted assays. J Anal Toxicol 44:245\u2013255. https:\/\/doi.org\/10.1093\/jat\/bkz083","journal-title":"J Anal Toxicol"},{"key":"745_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/cpdd.817","volume":"10","author":"I Landry","year":"2021","unstructured":"Landry I, Nakai K, Ferry J, Aluri J, Hall N, Lalovic B, Moline ML (2021) Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending-dose phase 1 studies in healthy adults. Clin Pharmacol Drug Dev 10:153\u2013165. https:\/\/doi.org\/10.1002\/cpdd.817","journal-title":"Clin Pharmacol Drug Dev"},{"key":"745_CR25","doi-asserted-by":"publisher","first-page":"23101","DOI":"10.1021\/acsomega.4c03976","volume":"9","author":"M Iqbal","year":"2024","unstructured":"Iqbal M, Haq N, Kalam MA, Imam F, Shakeel F (2024) A simple, sensitive, and greener HPLC-DAD method for the simultaneous analysis of two novel orexin receptor antagonists. ACS Omega 9:23101\u201323110. https:\/\/doi.org\/10.1021\/acsomega.4c03976","journal-title":"ACS Omega"},{"key":"745_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkaf032","author":"MM Gomonit","year":"2025","unstructured":"Gomonit MM, Skillman BN (2025) Quantification of daridorexant, lemborexant, and suvorexant in whole blood using liquid chromatography\u2013tandem mass spectrometry. J Anal Toxicol. https:\/\/doi.org\/10.1093\/jat\/bkaf032","journal-title":"J Anal Toxicol"},{"key":"745_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-025-00733-4","author":"B Waters","year":"2025","unstructured":"Waters B, Masuda M, Matsusue A, Kashiwagi M, Hori H, Ikematsu K, Kubo S (2025) The determination of the novel insomnia medication lemborexant using a validated liquid chromatography\u2013tandem mass spectrometry method, and its quantitation in clinical and forensic samples. Forensic Toxicol. https:\/\/doi.org\/10.1007\/s11419-025-00733-4","journal-title":"Forensic Toxicol"},{"key":"745_CR28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s12291-016-0557-x","volume":"31","author":"C Kumari","year":"2016","unstructured":"Kumari C, Varughese B, Ramji S, Kapoor S (2016) Liquid-liquid extraction and solid phase extraction for urinary organic acids: a comparative study from a resource constraint setting. Indian J Clin Biochem 31:414\u2013422. https:\/\/doi.org\/10.1007\/s12291-016-0557-x","journal-title":"Indian J Clin Biochem"},{"key":"745_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.chroma.2004.03.025","volume":"1043","author":"S Miyazaki","year":"2004","unstructured":"Miyazaki S, Morisato K, Ishizuka N, Minakuchi H, Shintani Y, Furuno M, Nakanishi K (2004) Development of a monolithic silica extraction tip for the analysis of proteins. J Chromatogr A 1043:19\u201325. https:\/\/doi.org\/10.1016\/j.chroma.2004.03.025","journal-title":"J Chromatogr A"},{"key":"745_CR30","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/jssc.200700627","volume":"31","author":"X Lee","year":"2008","unstructured":"Lee X, Hasegawa C, Kumazawa T, Shinmen N, Shoji Y, Seno H, Sato K (2008) Determination of tricyclic antidepressants in human plasma using pipette tip solid-phase extraction and gas chromatography\u2013mass spectrometry. J Sep Sci 31:2265\u20132271. https:\/\/doi.org\/10.1002\/jssc.200700627","journal-title":"J Sep Sci"},{"key":"745_CR31","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.chroma.2011.02.070","volume":"1218","author":"T Kumazawa","year":"2011","unstructured":"Kumazawa T, Hasegawa C, Uchigasaki S, Lee X, Suzuki O, Sato K (2011) Quantitative determination of phenothiazine derivatives in human plasma using monolithic silica solid-phase extraction tips and gas chromatography\u2013mass spectrometry. J Chromatogr A 1218:2521\u20132527. https:\/\/doi.org\/10.1016\/j.chroma.2011.02.070","journal-title":"J Chromatogr A"},{"key":"745_CR32","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/jssc.201100165","volume":"34","author":"A Namera","year":"2011","unstructured":"Namera A, Yamamoto S, Saito T, Miyazaki S, Oikawa H, Nakamoto A, Nagao M (2011) Simultaneous extraction of acidic and basic drugs from urine using mixed-mode monolithic silica spin column bonded with octadecyl and cation-exchange group. J Sep Sci 34:2232\u20132239. https:\/\/doi.org\/10.1002\/jssc.201100165","journal-title":"J Sep Sci"},{"key":"745_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.legalmed.2012.03.004","volume":"14","author":"C Hasegawa","year":"2012","unstructured":"Hasegawa C, Kumazawa T, Terada M, Lee X, Sato K, Uchigasaki S, Kurosaki K (2012) A new method for quantitative determination of dimemorfan in human plasma using monolithic silica solid-phase extraction tips. Leg Med (Tokyo) 14:267\u2013271. https:\/\/doi.org\/10.1016\/j.legalmed.2012.03.004","journal-title":"Leg Med (Tokyo)"},{"key":"745_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.chroma.2017.08.012","volume":"1517","author":"A Namera","year":"2017","unstructured":"Namera A, Saito T, Ota S, Miyazaki S, Oikawa H, Murata K, Nagao M (2017) Optimization and application of octadecyl-modified monolithic silica for solid-phase extraction of drugs in whole blood samples. J Chromatogr A 1517:9\u201317. https:\/\/doi.org\/10.1016\/j.chroma.2017.08.012","journal-title":"J Chromatogr A"},{"key":"745_CR35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11419-019-00471-4","volume":"37","author":"M Fujishiro","year":"2019","unstructured":"Fujishiro M, Noguchi A, Lee X, Hasegawa C, Kumazawa T, Miyazaki S, Kuriki A, Hashimoto M, Sato K, Matsuyama T (2019) A new method for high-resolution and high-precision analysis of flunitrazepam and 7-aminoflunitrazepam in human body fluids using a monolithic SPE spintip and UPLC\u2013Q-ToF\u2013MS. Forensic Toxicol 37:387\u2013397. https:\/\/doi.org\/10.1007\/s11419-019-00471-4","journal-title":"Forensic Toxicol"},{"key":"745_CR36","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH M10 Bioanalytical Method Validation and Study Sample Analysis. https:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524.pdf. Accessed Feb 2025."},{"key":"745_CR37","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.xphs.2024.10.030","volume":"114","author":"K Beran","year":"2025","unstructured":"Beran K, Abrahamsson B, Charoo N, Cristofoletti R, Holm R, Kambayashi A, Langguth P, Mehta M, Parr A, Polli JE, Shah VP, Dressman J (2025) Biowaiver monographs for immediate-release solid oral dosage forms: Lemborexant. J Pharm Sci 114:644\u2013659. https:\/\/doi.org\/10.1016\/j.xphs.2024.10.030","journal-title":"J Pharm Sci"},{"key":"745_CR38","unstructured":"Shionogi & Co., Ltd. Quviviq\u00ae: Interview Form. 3rd edition, revised in July 2025. (in Japanese) https:\/\/med.shionogi.co.jp\/products\/medicine\/quviviq\/interview-form_pdf.html. Accessed Aug 2025."},{"key":"745_CR39","first-page":"425","volume":"6","author":"S Siddhartha","year":"2018","unstructured":"Siddhartha S, Santosh T, Ratna V (2018) Development and validation of HPLC method for the determination of suvorexant in pharmaceutical dosage forms. Int J Pharm Drug Anal 6:425\u2013434","journal-title":"Int J Pharm Drug Anal"},{"key":"745_CR40","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/bcp.15029","volume":"88","author":"M Gehin","year":"2022","unstructured":"Gehin M, Wierdak J, Sabattini G, Sidharta PN, Dingemanse J (2022) Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist. Br J Clin Pharmacol 88:810\u2013819. https:\/\/doi.org\/10.1111\/bcp.15029","journal-title":"Br J Clin Pharmacol"},{"key":"745_CR41","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/s0731-7085(97)00185-4","volume":"16","author":"W He","year":"1997","unstructured":"He W, Parissis N (1997) Simultaneous determination of flunitrazepam and its metabolites in plasma and urine by HPLC\/DAD after solid phase extraction. J Pharm Biomed Anal 16:707\u2013715. https:\/\/doi.org\/10.1016\/s0731-7085(97)00185-4","journal-title":"J Pharm Biomed Anal"},{"key":"745_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/jat\/22.3.197","volume":"22","author":"I Deinl","year":"1998","unstructured":"Deinl I, Mahr G, von Meyer L (1998) Determination of flunitrazepam and its main metabolites in serum and urine by HPLC after mixed-mode solid-phase extraction. J Anal Toxicol 22:197\u2013202. https:\/\/doi.org\/10.1093\/jat\/22.3.197","journal-title":"J Anal Toxicol"},{"key":"745_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5665\/sleep.2386","volume":"36","author":"H Sun","year":"2013","unstructured":"Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, Ma J, Yee KL, Ermlich S, Mangin E, Lines C, Rosen L, Chodakewitz J, Murphy GM (2013) Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 36:259\u2013267. https:\/\/doi.org\/10.5665\/sleep.2386","journal-title":"Sleep"},{"key":"745_CR44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40261-019-00764-x","volume":"39","author":"RE Wrishko","year":"2019","unstructured":"Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK (2019) Effect of CYP3A inhibition and induction on the pharmacokinetics of suvorexant: two phase I, open-label, fixed-sequence trials in healthy subjects. Clin Drug Investig 39:441\u2013451. https:\/\/doi.org\/10.1007\/s40261-019-00764-x","journal-title":"Clin Drug Investig"}],"container-title":["Forensic Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-025-00745-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11419-025-00745-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-025-00745-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:46:10Z","timestamp":1769755570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11419-025-00745-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s11419-025-00745-0","relation":{},"ISSN":["1860-8965","1860-8973"],"issn-type":[{"value":"1860-8965","type":"print"},{"value":"1860-8973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted with the approval of the Ethics Committee of the Faculty of Medicine, Toho University (approval no. A24063). Plasma used for method validation was obtained from healthy volunteers after informed consent was obtained. For the measurement of plasma concentrations of ORAs in actual patients, the blood samples were collected either with informed consent or through an opt-out process following research information disclosure, ensuring that participants were given the opportunity to decline participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}